Altria Group Inc (Altria) is a manufacturer, and seller tobacco products, including cigarettes, cigars, oral tobacco products, and e-vapor products. Altria sells its products to wholesalers, distributors, chain stores, large retail organizations, and military, food, drug, convenience, dollar store, and mass merchandisers. The company market its products under the brand names of Marlboro, Black & Mild, Copenhagen, Skoal, and NJOY. The company serves U.S. tobacco consumers aged 21 and over, focusing on smokeable products, oral tobacco products, and e-vapor products.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Altria's R&D arm focuses on shifting its R&D investments from traditional tobacco businesses to new product platforms and technologies, focusing on tobacco harm reduction. The company's investment in research and technology supports the development of smoke-free products and the scientific evidence required for FDA product applications. Altria Group Inc is at the forefront of developing methodologies to assess the health impact of potentially reduced-risk nicotine products, following a rigorous scientific framework for evaluating these products and supporting FDA applications. The company is committed to transparent communication of research results and actively engages with the scientific community. The R&D units of Altria include the Regulatory Science team and the Regulatory Affairs team. The Regulatory Science team generates scientific evidence to demonstrate that smoke-free tobacco products result in lower exposure to harmful constituents and/or are lower risk compared to conventional cigarettes. The Regulatory Affairs team applies a rigorous framework to substantiate candidate products demonstrating protection of public health to bring new reduced-risk products to adult nicotine consumers aged 21 and over. Altria has a research and technology center in Richmond, Virginia, the US. In FY2025, the company incurred expenses of US$195 million on R&D, which as a percentage stood at 0.8%.